Testing a targeted pill for hard-to-treat solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these advanced cancers: ovarian, prostate cancer (CRPC), hormone-receptor positive/HER2-negative breast, endometrial, colorectal, small-cell lung, or pancreatic cancer
- Your cancer has either progressed after standard treatment or has no standard treatment proven to help
- You have at least one measurable tumor area on scans (measurable disease)
- Your energy/ability to do daily activities is rated as ECOG 0, 1, or 2
- You’re an adult (age 18 or older) and can sign the consent form
- You’re expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental tablet called TQB3217 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and helps shrink or control the tumor.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
Hear when a new Advanced Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.